Clinical Trials Browser

Phase 1 × atezolizumab × 30 days × Clear all

NCT03321643 2026-03-18

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Phase 1 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06496568 2026-03-18

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers

Phase 1 Recruiting

PIK3CA-Mutated Cancers

NCT06066138 2026-03-11

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Phase 1 Recruiting

DermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Alveolar Soft Part, Small Cell Lung Carcinoma

NCT04020809 2026-03-09

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Phase 1 Active not recruiting

Melanoma

NCT06031441 2026-03-06

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Locally Advanced Solid Tumors

NCT04929223 2026-03-03

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase 1 Active not recruiting

Bites and Stings, Lung Neoplasms

NCT06537310 2026-03-03

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

Cancer-Neoplasms

NCT06492954 2026-03-02

AflacST2301

Phase 1 Recruiting

Osteosarcoma

NCT06616623 2026-02-27

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04250155 2026-02-24

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT06760481 2026-02-24

Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

Phase 1 Active not recruiting

Advanced Solid Malignancies

NCT05488522 2026-02-20

SBRT With Atezo/Bev for HCC

Phase 1 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular